Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
If approved, investigational semaglutide 7.2 mg injection would offer the optionality of a higher dose for greater weight…
Novo Nordisk’s CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek® USA – English USA – English
A post hoc analysis of REDEFINE 1 demonstrated a 10.9 mmHg reduction in systolic blood pressure with investigational…